Proteasome Inhibition Reveals that a Functional Preintegration Complex Intermediate Can Be Generated during Restriction by Diverse TRIM5 Proteins
Anderson, Jenny L.
Campbell, Edward M.
Hope, Thomas J.
MetadataShow full item record
CitationAnderson, J. L., E. M. Campbell, X. Wu, N. Vandegraaff, A. Engelman, and T. J. Hope. 2006. “Proteasome Inhibition Reveals That a Functional Preintegration Complex Intermediate Can Be Generated during Restriction by Diverse TRIM5 Proteins.” Journal of Virology 80 (19): 9754–60. https://doi.org/10.1128/jvi.01052-06.
AbstractThe primate TRIM5 proteins constitute a class of restriction factors that prevent host cell infection by retroviruses from different species. The TRIM5 proteins act early after virion entry and prevent viral reverse transcription products from accumulating. We recently found that proteasome inhibitors altered the rhesus monkey TRIM5 alpha restriction of human immunodeficiency virus type 1 (HIV-1), allowing reverse transcription products to accumulate even though viral infection remained blocked. To assess whether sensitivity to proteasome inhibitors was a common feature of primate TRIM5 proteins, we conducted a similar analysis of restriction mediated by owl monkey TRIM-cyclophilin A (CypA) or human TRIM5 alpha. Similar to rhesus monkey TRIM5 alpha restriction, proteasome inhibition prevented owl monkey TRIM-CypA restriction of HIV-1 reverse transcription, even though HIV-1 infection and the output of 2-LTR circles remained impaired. Likewise, proteasome inhibition alleviated human TRIM5 alpha restriction of N-tropic murine leukemia virus reverse transcription. Finally, HIV-1 reverse transcription products escaping rhesus TRIM5 alpha restriction by proteasome inhibition were fully competent for integration in vitro, demonstrating that TRIM5 alpha likely prevents the viral cDNA from accessing chromosomal target DNA. Collectively, these data indicate that the diverse TRIM5 proteins inhibit retroviral infection in multiple ways and that inhibition of reverse transcription products is not necessary for TRIM5-mediated restriction of retroviral infection.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:41482982
- HMS Scholarly Articles